Venu Krishna, Barclays Managing Director & Head of U.S. Equity Strategy, joins 'Fast Money' to talk the recent market rally, what it means for investing at this point, and more. Supreme Court hands ...
Santos supplied 27 points (8-12 FG, 3-5 3Pt, 8-9 FT), four rebounds and four assists across 33 minutes during Friday's 131-126 victory over the Wizards. The Brazilian forward is one of several players ...
US broadcaster Stephen Colbert has big plans to keep himself busy when his talk show goes off the air in May. In the early hours of Wednesday morning, it was announced that Colbert will be co-writing ...
Jeffrey Gundlach, DoubleLine Capital founder and CEO, joins 'Closing Bell' to discuss Gundlach's broad view on equity markets, the commodity complex and much more. Breaking: Trump says 'effective ...
Kurdish Iranian dissident groups based in northern Iraq are preparing for a potential cross-border military operation in Iran, and the US has asked Iraqi Kurds to support them, Kurdish officials tell ...
The fifth entry in the acclaimed co-op puzzle series We Were Here series has been announced. It's known as We Were Here Tomorrow, and according to independent developer Total Mayhem Games this next ...
Israeli source says Lebanon op could include ground offensive, no immunity for any Hezbollah members By Emanuel Fabian 2 March 2026, 9:11 am ...
TIE Fighter: Total Conversion goes from strength to strength. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works.
This AAAS program will allow the Graduate School to better target students with disabilities for its longstanding SMART program The Graduate School’s Office of Graduate Access and Retention (GAR) is ...
(PRO Views are exclusive to PRO subscribers, giving them insight on the news of the day direct from a real investing pro. See the full discussion above.) Investor Jay Woods is keeping a close eye on ...
NextPoint Therapeutics Announces Clinical Entry of NPX372, a First-in-Class B7-H7–Targeted T Cell Engager to Treat Solid Tumors Initiates first-in-human clinical studies of an IgG-like CD3 bispecific ...